| General Information | |
|---|---|
| ZINC ID | ZINC000049070903 |
| Molecular Weight (Da) | 447 |
| SMILES | O=C(NN1CCCCC1)N1CCN([C@H](c2ccccc2)c2ccc(Cl)cc2Cl)CC1 |
| Molecular Formula | C23Cl2N4O1 |
| Action | Inverse Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 123.522 |
| HBA | 2 |
| HBD | 1 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 30 |
| LogP | 5.809 |
| Activity (Ki) in nM | 1.2023 |
| Polar Surface Area (PSA) | 38.82 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | + |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | - |
| Cyp2d6 substrate | + |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | + |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 1.022 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 12 |
| Fraction csp3 | 0.43 |
| Ilogp | 4.07 |
| Xlogp3 | 4.89 |
| Wlogp | 3.34 |
| Mlogp | 4.47 |
| Silicos-it log p | 3.54 |
| Consensus log p | 4.06 |
| Esol log s | -5.59 |
| Esol solubility (mg/ml) | 0.00114 |
| Esol solubility (mol/l) | 0.00000254 |
| Esol class | Moderately |
| Ali log s | -5.44 |
| Ali solubility (mg/ml) | 0.00162 |
| Ali solubility (mol/l) | 0.00000362 |
| Ali class | Moderately |
| Silicos-it logsw | -6.58 |
| Silicos-it solubility (mg/ml) | 0.000118 |
| Silicos-it solubility (mol/l) | 0.00000026 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -5.56 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 0 |
| Muegge number of violations | 0 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 2 |
| Synthetic accessibility | 3.78 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -4.18 |
| Logd | 4.343 |
| Logp | 4.358 |
| F (20%) | 0.004 |
| F (30%) | 0.021 |
| Mdck | - |
| Ppb | 96.47% |
| Vdss | 1.225 |
| Fu | 4.24% |
| Cyp1a2-inh | 0.054 |
| Cyp1a2-sub | 0.446 |
| Cyp2c19-inh | 0.752 |
| Cyp2c19-sub | 0.935 |
| Cl | 6.079 |
| T12 | 0.068 |
| H-ht | 0.958 |
| Dili | 0.617 |
| Roa | 0.497 |
| Fdamdd | 0.445 |
| Skinsen | 0.048 |
| Ec | 0.003 |
| Ei | 0.007 |
| Respiratory | 0.923 |
| Bcf | 0.843 |
| Igc50 | 3.986 |
| Lc50 | 5.739 |
| Lc50dm | 3.519 |
| Nr-ar | 0.257 |
| Nr-ar-lbd | 0.003 |
| Nr-ahr | 0.851 |
| Nr-aromatase | 0.017 |
| Nr-er | 0.328 |
| Nr-er-lbd | 0.009 |
| Nr-ppar-gamma | 0.006 |
| Sr-are | 0.471 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.013 |
| Sr-mmp | 0.566 |
| Sr-p53 | 0.86 |
| Vol | 436.882 |
| Dense | 1.021 |
| Flex | 0.24 |
| Nstereo | 1 |
| Nongenotoxic carcinogenicity | 1 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 1 |
| Surechembl | 0 |
| Nonbiodegradable | 1 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | - |
| Toxicophores | 0 |
| Qed | 0.731 |
| Synth | 2.819 |
| Fsp3 | 0.435 |
| Mce-18 | 74.455 |
| Natural product-likeness | -1.361 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | - |
| Gsk | Rejected |
| Goldentriangle | Accepted |